Abstract
The Aligning Science Across Parkinson’s (ASAP) initiative was set up to improve understanding of the biology underlying the onset and progression of Parkinson’s disease. With an emphasis on open science and collaboration, we have assembled a research network led by nearly 100 investigators to explore the pathology of Parkinson’s disease, and this network will soon expand to include researchers working on relevant (dys)-functional neural circuits. We have also contributed to large-scale genetics and patient cohort initiatives related to the disease. We hope that these actions, and others planned for the future, will deepen our knowledge of the molecular mechanisms underlying the origin and evolution of Parkinson’s disease and, ultimately, contribute to the development of novel therapies.
Longevity Acquisition Corporation Announces 4D pharma Joining Landmark Parkinson s Progression Markers Initiative
News provided by
Share this article
Share this article
NEW YORK, Dec. 21, 2020 /PRNewswire/ Longevity Acquisition Corporation (NASDAQ: LOAC) (the Company ), a publicly-traded special purpose acquisition company, announced today that on December 18, 2020, 4D pharma plc (AIM: DDDD) ( 4D pharma ), a pharmaceutical company leading the development of Live Biotherapeutic products ( LBPs ) - a novel class of drug derived from the microbiome, and a business combination target of LOAC, has joined the Parkinson s Progression Markers Initiative ( PPMI ) as an industry partner. PPMI is a landmark study sponsored by The Michael J. Fox Foundation to better understand Parkinson s disease and accelerate the development of new treatments.
18 December 2020 | 14:04pm
StockMarketWire.com - 4D pharma said it has joined the Parkinson s Progression Markers Initiative (PPMI), a study sponsored by The Michael J Fox Foundation (MJFF) to better understand Parkinson s disease and accelerate the development of new treatments.
The study was launched by MJFF in 2010 to help identify, develop, and validate biomarkers of Parkinson s disease progression to further the development of disease-modifying therapies.
PPMI is funded by MJFF and a consortium of key industry players, non-profit organizations and private individuals, and involves active participation of stakeholders from government, the biopharmaceutical industry and academia.
Alex Stevenson, chief scientific officer at 4D pharma said: The Michael J Fox Foundation has made considerable contributions to the development of therapeutic solutions for the millions of people with Parkinson s disease.
4D Pharma Joins Landmark Study For Parkinson s Treatment Development
Fri, 18th Dec 2020 10:13
(Alliance News) - 4D Pharma PLC on Friday said its has joined the Parkinson s Progression Markers Initiative, a study for the better understanding of Parkinson s disease and the development of new treatments, sponsored by the Michael J Fox Foundation.
The study was first launched in 2010 to help identify, develop, and validate biomarkers of Parkinson s disease progression to further the development of disease-modifying therapies.
Under the initiative, the Leeds-based pharmaceutical company will contribute towards the programme by joining the Partner Scientific Advisory Board, which is involved in the design of the study. In addition, 4D Pharma will also join several working groups for the discussion of data and address Parkinson s clinical trial challenges with other partners.
4D pharma Joins Landmark Parkinson s Progression Markers Initiative A landmark study sponsored by The Michael J. Fox Foundation to better understand Parkinson s disease and accelerate the development of new treatments 4D pharma will play an important role as PPMI considers the microbiome as an area of focus Leeds, UK, December l8, 2020 , - 4D pharma plc (AIM: DDDD), a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs) - a novel class of drug derived from the microbiome, today announces that it has joined the Parkinson s Progression Markers Initiative (PPMI) as an industry partner. PPMI is a landmark study sponsored by The Michael J. Fox Foundation to better understand Parkinson s disease and accelerate the development of new treatments.